FDA Accepts Supplement for STELARA (Ustekinumab) by Centocor Ortho Biotech
The FDA has accepted a supplemental application for STELARA (ustekinumab) from Centocor Ortho Biotech.
Asset / Drug
Drug and asset intelligence for STELARA with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
23 Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.